Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
The combination of zanzalintinib plus nivolumab demonstrated encouraging preliminary activity with manageable safety.
Yale physician-scientist David Braun, MD, PhD, and a research team created personalized vaccines that kept patients cancer-free for about three years.
There appeared to be no extra benefit with the addition of nivolumab to tivozanib among patients included in the phase 3 TiNivo-2 trial.
As the US population continues to age, understanding the relative efficacy of renal cell carcinoma (RCC) treatment in older patients is “essential ...
Jad Chahoud, MD, MPH, MHA, discusses the mechanism of action for zanzalintinib and walks through key design elements of the STELLAR-002 trial.
The regimen showed activity regardless of the prior immunotherapy-based combination used in the first-line setting.
Panelists discuss how the new tracing agent (Zr-DFO-girentuximab or 2050) works by binding to carbonic anhydrase IX, an enzyme expressed on the surface of most clear cell renal cancers, coupled with zirconium for radiographic detection.
Panelists discuss how the ZIRCON trial demonstrated high positive predictive value (> 90%) for identifying clear cell renal cell carcinoma using a new molecular imaging agent, though negative predictive value was lower at approximately 70%.
Background Immune checkpoint inhibitors (ICIs) are a cornerstone of modern cancer treatment, but their effectiveness is limited. Fecal microbiota transplantation (FMT), which alters the gut microbiome, has shown promise in enhancing ICIs’ therapeutic effects. Methods We conducted a ...
Renal cell carcinoma (RCC), particularly the clear-cell subtype (ccRCC), accounts for 75-85% of kidney cancers and exhibits distinct genetic and ...
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.